Ipilimumab (αCTLA-4) became the first FDA approved T cell checkpoint antibody for use against melanoma, with patients showing a 13% objective response rate against Stage III/IV melanoma, with largely manageable immune-related adverse events (7–9). Here, TBXT is linked to melanoma.